Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Celgene Trial Disappointment No Disaster

In this video, Motley Fool health-care analyst David Williamson discusses some phase 3 trial results for Celgene's (NASDAQ: CELG  ) pipeline drug Apremilast in the treatment of psoriasis. Investor excitement over the drug had been raised to a fever pitch, so when the drug failed to hit the same high marks it had reached in phase 2, there was some disappointment. However, in the video, David tells investors everything that the drug still has going for it, and why it may have a leg up on the competition in this space.

Can Celgene continue to soar?
Every in-the-know biotech investor has an eye on Celgene. Shares have skyrocketed this year as the company outlined a plan to almost triple its profits in only a few years. But should you buy the story Celgene is selling? Make sure you understand the key opportunities and risks facing this company by picking up The Motley Fool's brand-new premium report on Celgene. To claim your copy today -- along with a free year of updates -- simply click here now.

Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2292281, ~/Articles/ArticleHandler.aspx, 9/28/2016 3:23:53 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,313.22 84.92 0.47%
S&P 500 2,167.48 7.55 0.35%
NASD 5,311.59 5.88 0.11%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/28/2016 3:08 PM
CELG $105.70 Down -1.70 -1.58%
Celgene CAPS Rating: *****
AMGN $169.90 Down -1.73 -1.01%
Amgen CAPS Rating: ****
PFE $33.96 Up +0.13 +0.39%
Pfizer CAPS Rating: ****